These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18022543)

  • 1. Tumor microenvironment and immune escape.
    Ferrone S; Whiteside TL
    Surg Oncol Clin N Am; 2007 Oct; 16(4):755-74, viii. PubMed ID: 18022543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.
    Poggi A; Zocchi MR
    Arch Immunol Ther Exp (Warsz); 2006; 54(5):323-33. PubMed ID: 17031467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?
    Rouas-Freiss N; Moreau P; Ferrone S; Carosella ED
    Cancer Res; 2005 Nov; 65(22):10139-44. PubMed ID: 16287995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure, expression and function of HLA-G in renal cell carcinoma.
    Seliger B; Schlaf G
    Semin Cancer Biol; 2007 Dec; 17(6):444-50. PubMed ID: 17707652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
    Huang Y; Shah S; Qiao L
    Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis?
    Chang CC; Campoli M; Ferrone S
    Curr Opin Immunol; 2004 Oct; 16(5):644-50. PubMed ID: 15342012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of immune escape of cancer and its regulation.
    Morita R; Hirohashi Y; Torigoe T
    Rinsho Ketsueki; 2009 May; 50(5):375-80. PubMed ID: 19483397
    [No Abstract]   [Full Text] [Related]  

  • 8. Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?
    Salih HR; Nüssler V
    Eur J Med Res; 2001 Aug; 6(8):323-32. PubMed ID: 11549514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: do they provide tumor cells with escape mechanisms from recognition by cytotoxic T lymphocytes?
    Bangia N; Ferrone S
    Immunol Invest; 2006; 35(3-4):485-503. PubMed ID: 16916763
    [No Abstract]   [Full Text] [Related]  

  • 10. Non-classical HLA-G antigen and its role in the cancer progression.
    Tripathi P; Agrawal S
    Cancer Invest; 2006 Mar; 24(2):178-86. PubMed ID: 16537188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells.
    Offner S; Hofmeister R; Romaniuk A; Kufer P; Baeuerle PA
    Mol Immunol; 2006 Feb; 43(6):763-71. PubMed ID: 16360021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
    Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
    Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?
    Wischhusen J; Waschbisch A; Wiendl H
    Semin Cancer Biol; 2007 Dec; 17(6):459-68. PubMed ID: 17768067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HLA-E molecule induction on the surface of tumor cells protects them from cytotoxic lymphocytes].
    Berezhnoĭ AE; Chernisheva AD; Zakeeva IR; Danilova AB; Danilov AO; Moiseenko VM; Geraghty D; Gnuchev NV; Georgiev GP; Kibardin AV; Larin SS
    Vopr Onkol; 2009; 55(2):224-9. PubMed ID: 19514381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation.
    Takahara M; Miyai M; Tomiyama M; Mutou M; Nicol AJ; Nieda M
    J Leukoc Biol; 2008 Mar; 83(3):742-54. PubMed ID: 18156189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cytotoxic T lymphocytes in cancer and autoimmunity].
    Prado-García H; Avila-Moreno F; López-González JS
    Rev Invest Clin; 2004; 56(5):629-39. PubMed ID: 15776868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1.
    Gajewski TF
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1279-83. PubMed ID: 15648949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer.
    Ferris RL; Whiteside TL; Ferrone S
    Clin Cancer Res; 2006 Jul; 12(13):3890-5. PubMed ID: 16818683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell responses.
    Xie Y; Bai O; Yuan J; Chibbar R; Slattery K; Wei Y; Deng Y; Xiang J
    Cancer Res; 2009 Oct; 69(19):7756-66. PubMed ID: 19789353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKG2D ligands in tumor immunity.
    Nausch N; Cerwenka A
    Oncogene; 2008 Oct; 27(45):5944-58. PubMed ID: 18836475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.